281 related articles for article (PubMed ID: 28656379)
1. Physiology and pathophysiology of the plasminogen system in the kidney.
Svenningsen P; Hinrichs GR; Zachar R; Ydegaard R; Jensen BL
Pflugers Arch; 2017 Nov; 469(11):1415-1423. PubMed ID: 28656379
[TBL] [Abstract][Full Text] [Related]
2. Amiloride Reduces Urokinase/Plasminogen-Driven Intratubular Complement Activation in Glomerular Proteinuria.
Isaksson GL; Hinrichs GR; Andersen H; Bach ML; Weyer K; Zachar R; Henriksen JE; Madsen K; Lund IK; Mollet G; Bistrup C; Birn H; Jensen BL; Palarasah Y
J Am Soc Nephrol; 2024 Apr; 35(4):410-425. PubMed ID: 38254266
[TBL] [Abstract][Full Text] [Related]
3. Plasmin is not protective in experimental renal interstitial fibrosis.
Edgtton KL; Gow RM; Kelly DJ; Carmeliet P; Kitching AR
Kidney Int; 2004 Jul; 66(1):68-76. PubMed ID: 15200414
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of renal NaCl retention in proteinuric disease.
Svenningsen P; Friis UG; Versland JB; Buhl KB; Møller Frederiksen B; Andersen H; Zachar RM; Bistrup C; Skøtt O; Jørgensen JS; Andersen RF; Jensen BL
Acta Physiol (Oxf); 2013 Mar; 207(3):536-45. PubMed ID: 23216619
[TBL] [Abstract][Full Text] [Related]
5. Podocyte injury: the role of proteinuria, urinary plasminogen, and oxidative stress.
Raij L; Tian R; Wong JS; He JC; Campbell KN
Am J Physiol Renal Physiol; 2016 Dec; 311(6):F1308-F1317. PubMed ID: 27335373
[TBL] [Abstract][Full Text] [Related]
6. Urokinase-type plasminogen activator (uPA) is not essential for epithelial sodium channel (ENaC)-mediated sodium retention in experimental nephrotic syndrome.
Bohnert BN; Daiminger S; Wörn M; Sure F; Staudner T; Ilyaskin AV; Batbouta F; Janessa A; Schneider JC; Essigke D; Kanse S; Haerteis S; Korbmacher C; Artunc F
Acta Physiol (Oxf); 2019 Dec; 227(4):e13286. PubMed ID: 31006168
[TBL] [Abstract][Full Text] [Related]
7. Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine.
Stæhr M; Buhl KB; Andersen RF; Svenningsen P; Nielsen F; Hinrichs GR; Bistrup C; Jensen BL
Am J Physiol Renal Physiol; 2015 Aug; 309(3):F235-41. PubMed ID: 25972510
[TBL] [Abstract][Full Text] [Related]
8. Endogenous urokinase lacks antifibrotic activity during progressive renal injury.
Yamaguchi I; Lopez-Guisa JM; Cai X; Collins SJ; Okamura DM; Eddy AA
Am J Physiol Renal Physiol; 2007 Jul; 293(1):F12-9. PubMed ID: 17356128
[TBL] [Abstract][Full Text] [Related]
9. Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-to-mesenchymal transition: role of plasmin-activated signals.
Zhang G; Kernan KA; Collins SJ; Cai X; López-Guisa JM; Degen JL; Shvil Y; Eddy AA
J Am Soc Nephrol; 2007 Mar; 18(3):846-59. PubMed ID: 17267741
[TBL] [Abstract][Full Text] [Related]
10. The fibrinolytic system: A new target for treatment of depression with psychedelics.
Idell RD; Florova G; Komissarov AA; Shetty S; Girard RB; Idell S
Med Hypotheses; 2017 Mar; 100():46-53. PubMed ID: 28236848
[TBL] [Abstract][Full Text] [Related]
11. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
12. The plasminogen activator/plasmin system is up-regulated after acute necrotizing pancreatitis in human beings.
Friess H; Duarte R; Kleeff J; Fukuda A; Tang WH; Graber H; Schilling M; Zimmermann A; Korc M; Büchler MW
Surgery; 1998 Jul; 124(1):79-86. PubMed ID: 9663255
[TBL] [Abstract][Full Text] [Related]
13. Plasmin in nephrotic urine activates the epithelial sodium channel.
Svenningsen P; Bistrup C; Friis UG; Bertog M; Haerteis S; Krueger B; Stubbe J; Jensen ON; Thiesson HC; Uhrenholt TR; Jespersen B; Jensen BL; Korbmacher C; Skøtt O
J Am Soc Nephrol; 2009 Feb; 20(2):299-310. PubMed ID: 19073825
[TBL] [Abstract][Full Text] [Related]
14. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
Kenichi M; Masanobu M; Takehiko K; Shoko T; Akira F; Katsushige A; Takashi H; Yoshiyuki O; Shigeru K
J Lab Clin Med; 2004 Aug; 144(2):69-77. PubMed ID: 15322501
[TBL] [Abstract][Full Text] [Related]
15. Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension.
Oxlund CS; Buhl KB; Jacobsen IA; Hansen MR; Gram J; Henriksen JE; Schousboe K; Tarnow L; Jensen BL
J Am Soc Hypertens; 2014 Dec; 8(12):872-81. PubMed ID: 25492830
[TBL] [Abstract][Full Text] [Related]
16. Staphylokinase reduces plasmin formation by endogenous plasminogen activators.
Jin T; Bokarewa M; Zhu Y; Tarkowski A
Eur J Haematol; 2008 Jul; 81(1):8-17. PubMed ID: 18331597
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice.
Lund LR; Green KA; Stoop AA; Ploug M; Almholt K; Lilla J; Nielsen BS; Christensen IJ; Craik CS; Werb Z; Danø K; Rømer J
EMBO J; 2006 Jun; 25(12):2686-97. PubMed ID: 16763560
[TBL] [Abstract][Full Text] [Related]
18. Biotin-Chasing Assay to Evaluate uPAR Stability and Cleavage on the Surface of Cells.
Leksa V; Schiller HB; Stockinger H
Methods Mol Biol; 2018; 1731():39-47. PubMed ID: 29318541
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of plasminogen activation protects against ganglion cell loss in a mouse model of retinal damage.
Zhang X; Chaudhry A; Chintala SK
Mol Vis; 2003 Jun; 9():238-48. PubMed ID: 12813409
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation.
Gupta KK; Donahue DL; Sandoval-Cooper MJ; Castellino FJ; Ploplis VA
Sci Rep; 2017 Mar; 7(1):365. PubMed ID: 28336948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
